AKT1 and B-cell chronic lymphocytic leukemia: Inhibition of BTK disrupts downstream signalling pathways which enhance CLL cell survival, such as v-akt murine thymoma viral oncogene (AKT), extracellular receptor kinase (ERK) and Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kB)[83-86].